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ABSTRACT 
ALLERGIC INFLAMMATION IN THE NASAL MUCOSA 
A Clinical, Morphological and Biochemical Study in Allergic Rhinitis 
with Special Reference to Mast Cells 
SIGURDUR JULIUS S ON, M.D., Departments of Otolaryngology Head & Neck Surgery and 
Pathology, University of Göteborg, Sahlgrenska Hospital, S-4I3 45 Göteborg, Sweden. 
Mast cells are the primary effector cells in acute allergic reactions in mucosal membranes and 
in the skin. The acute symptoms after allergen exposure of the sensitised individual are 
mainly caused by mast-cell-derived mediators. The aim of this study was to investigate the 
function of the mast cell in allergic inflammation by morphological and biochemical analysis 
of the nasal mucosa and by clinical study of patients with seasonal allergic rhinitis before and 
after allergen provocation as well as before and during the pollen season. Nasal biopsies were 
performed and brush and lavage samples were collected from the nasal mucosa. Mast cells 
were morphologically identified based on their metachromatic properties on staining with 
toluidine blue as well as with immunohistological methods with monoclonal antibodies 
against IgE, and two mast cell proteases, tryptase and chymase. Sensitivity to aldehyde 
fixation on metachromacy was studied. The histamine content of tissue samples was 
determined by high performance liquid chromatography. The levels of histamine and tryptase 
in the returned fluid of nasal lavages were analysed by radioimmunoassay and the TAME-
esterase activity in the lavage fluid was determined with a radiochemical method. The effects 
of topical treatment with corticosteroids were studied. 
Mast cells were found in increased numbers in the nasal epithelium in patients with allergic 
rhinitis even when free of symptoms. This increase in intra-epithelial cells consisted mostly 
of cells containing tryptase and lacking chymase but also of cells containing both tryptase and 
chymase. There was also an increase in the stroma of mast cells containing tryptase only. The 
metachromatic staining properties of mast cells in the specimens from the allergic patients 
were found to be decreased and highly aldehyde sensitive. The numbers of mast cells in the 
epithelium before allergen provocation correlated with nasal symptoms after the provocation-
After an initial decrease after the allergen challenge, the numbers of metachromatic, tryptase-
containing and IgE-bearing cells increased as well as the histamine content of cellular 
material from the nasal epithelium. The levels of histamine and tryptase and the TAME-
esterase activity in the lavage fluid increased after allergen provocation. After topical 
treatment with a corticosteroid a decrease was found in the post allergen challenge symptoms 
and tryptase levels in the lavage fluid as well as the density of those mast ceils in the 
epithelium that contained tryptase but lacked chymase. 
It was concluded that the mast cell plays an unequivocal role in the inflammation of allergic 
diseases in mucosal membranes, The functional properties of mast cells found at the site of 
the inflammation are altered. The lack of chymase and the decrease in metachromatic staining 
capacity combined with an increase in aldehyde sensitivity reflects a functional activation of 
the mast cells, rather than phenotypic differentiation related to anatomical site. The beneficial 
effects on allergic symptoms after topical corticosteroid treatment may to some extent be 
explained through a decrease in the density of mast cells in the shock organ. 
Key words: Allergic rhinitis, nasal mucosa, allergen challenge, mast cells, eosinophil 
granulocytes, basophils, histamine, tryptase, chymase, immunohistochemsitry. 
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ABSTRACT 
ALLERGIC INFLAMMATION IN THE NASAL MUCOSA. A Clinical, Morphological and 
Biochemical Study in Allergic Rhinitis with Special Reference to Mast Cells 
SIGURDUR JULIUSSON, M.D., Departments of Otolaryngology Head & Neck Surgery, 
and Pathology, University of Göteborg, Sahlgrenska Hospital, S-413 45 Göteborg, Sweden, 
Mast cells are the primary effector cells in acute allergic reactions in mucosal membranes and 
in the skin. The acute symptoms after allergen exposure of the sensitised individual are 
mainly caused by mast-cell-derived mediators. The aim of this study was to investigate the 
function of the mast cell in allergic inflammation by morphological and biochemical analysis 
of the nasal mucosa and by clinical study of patients with seasonal allergic rhinitis before and 
after allergen provocation as well as before and during the pollen season. Nasal biopsies were 
performed and brush and lavage samples were collected from the nasal mucosa. Mast cells 
were morphologically identified based on their metachromatic properties on staining with 
toluidine blue as well as with immunohistological methods with monoclonal antibodies 
against IgE, and two mast cell proteases, tryptase and chymase. Sensitivity to aldehyde 
fixation on metachromacy was studied. The histamine content of tissue samples was 
determined by high performance liquid chromatography. The levels of histamine and tryptase 
in the returned fluid of nasal lavages were analysed by radioimmunoassay and the TAME-
esterase activity in the lavage fluid was determined with a radiochemical method. The effects 
of topical treatment with corticosteroids were studied. 
Mast cells were found in increased numbers in the nasal epithelium in patients with allergic 
rhinitis even when free of symptoms. This increase in intra-epithelial cells consisted mostly 
of cells containing tryptase and lacking chymase but also of cells containing both tryptase and 
chymase. There was also an increase in the stroma of mast cells containing tryptase only. The 
metachromatic staining properties of mast cells in the specimens from the allergic patients 
were found to be decreased and highly aldehyde sensitive. The numbers of mast cells in the 
epithelium before allergen provocation correlated with nasal symptoms after the provocation. 
After an initial decrease after the allergen challenge, the numbers of metachromatic, tryptase-
containing and IgE-bearing cells increased as well as the histamine content of cellular 
material from the nasal epithelium. The levels of histamine and tryptase and the TAME-
esterase activity in the lavage fluid increased after allergen provocation. After topical 
treatment with a corticosteroid a decrease was found in the post allergen challenge symptoms 
and tryptase levels in the lavage fluid as well as the density of those mast cells in the 
epithelium that contained tryptase but lacked chymase. 
It was concluded that the mast cell plays an unequivocal role in the inflammation of allergic 
diseases in mucosal membranes. The functional properties of mast cells found at the site of 
the inflammation are altered. The lack of chymase and the decrease in metachromatic staining 
capacity combined with an increase in aldehyde sensitivity reflects a functional activation of 
the mast cells, rather than phenotypic differentiation related to anatomical site. The beneficial 
effects on allergic symptoms after topical corticosteroid treatment may to some extent be 
explained through a decrease in the density of mast cells in the shock organ. 
Key words: Allergic rhinitis, nasal mucosa, allergen challenge, mast cells, eosinophil 
granulocytes, basophils, histamine, tryptase, chymase, immunohistochemsitry. 
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ABBREVIATIONS 
ACE angiotensin converting enzyme 
APAAP alkaline phosphatase-anti-alkaline phosphatase 
BU biological units 
CD clusters of differentiation 
cpm counts per minute 
CTMC connective tissue mast cells 
Da Dalton 
ECF-A eosinophil chemotactic factor of anaphylaxis 
GM-CSF granulocyte/macrophage colony stimulating factor 
h hour(s) 
HPLC highly purified liquid chromatography 
IFAA iso-osmotic formaldehyde acetic acid 
Ig immunoglobulin 
IL interleukin 
IFN interferon 
LPR late-phase reactions 
LTB4 leukotriene B4 (also LTC4, LTD4, LTE4) 
MBP major basic protein 
MCT tryptase only positive mast cells 
MCTC tryptase and chymase positive mast cells 
MMC mucosal mast cells 
min minute(s) 
mol wt molecular weight 
NCF-A neutrophil chemotactic factor of anaphylaxis 
PAF platelet-activating factor 
PAP peroxidase-anti-peroxidase 
PGD2 prostaglandin D2 (also PGE2, PGF2) 
PGI2 prostacyclin 
PPD purified protein derivative 
RIA radioimmunoassay 
RIACT radioimmunoassay on coated tubes 
RNA ribonucleic acid 
SCF stem cell factor 
SEM standard error of the mean 
SRS-A slow reacting substances of anaphylaxis 
TAME N-a-tosyl-L-arginine-methyl ester 
TNFa tumor necrosis factor-a 
TXA2 thromboxane A? 
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INTRODUCTION 
The first known indication of allergic hyperactivity occurred about 5000 years ago. It was the 
first ruler of the first dynasty in ancient Egypt, Pharaoh Menes of Memphis, who died after 
having been stung by a hornet. As a sufferer of hay fever, Charles Blackley established in 
1873 for the first time beyond any doubt that pollen caused hay f ever (Blackley 1873). At the 
beginning of the 20th century von Pirquet and Shick proposed the term allergy (from the 
Greek words alios "changed" and ergos "action") for a changed reactivity to staphylococcal 
antitoxin serum in children (von Pirquet and Schick 1906). 
Cooke and Coca coined the term atopy for a cluster of diseases, namely, asthma, hay fever, 
urticaria and anaphylactic reactions, all with a familial tendency of occurrence (Coca and 
Cooke 1923). Atopic dermatitis was later added to this list. Today the term atopy refers to a 
hereditary predisposition to overproduction of antibodies of the IgE type. The risk of 
developing an allergic disease is increased in parallel to an increased incidence of IgE-
mediated disease in one or both parents (Kjellman 1977, Åberg et al. 1989). The atopic 
individual may suffer from one or more of the atopic diseases which characteristically start at 
different ages. The more atopic the individual, the earlier the first appearance of symptoms. 
Gastrointestinal allergy starts in infancy and is followed by atopic dermatitis. During 
childhood the individual develops atopic asthma while allergic rhinitis often starts in early 
adolescence. The sensitisation to the allergen persists, but the disease often decreases in 
intensity with age. 
It seems certain that there has been an increase in the occurrence of both allergic rhinitis and 
asthma in many if not all the industrialised nations (Wiirthrich 1989, Åberg 1989). The 
differences in incidence from one community to another present a picture of a group of 
conditions where potentially alterable environmental factors certainly play a role (Peat et al. 
1987, Åberg 1989). Today, allergy and other forms of hyperreactivity are so common in the 
Nordic countries that they constitute a major public health problem. Annually, nearly one-
third of the population experiences some sort of hypersensitivity or allergy, and over a 
lifetime nearly half of the population experience a hypersensitive reaction. Some differences 
do exist between the scientific/medical concepts of allergy and the popular definition, 
however (Consensus Statement 1992). 
Inhalation of allergens can cause allergic reactions in the nose and/or the bronchi of the 
sensitised individual. The nasal reaction causes sneezing, itching, congestion and rhinorrhea 
while the bronchial reaction is due to narrowing of the airways by constriction, mucosal 
swelling and increased secretion. 
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The central feature of allergic rhinitis is an inflammation of the nasal mucous membrane. The 
mast cell, with IgE on its surface, is the primary affector cell in this process. Activation of the 
cell initiates a cascade of reactions starting with the release of inflammatory mediators, such 
as histamine, leading to recruitment of new inflammatory cells resulting in an ongoing 
inflammatory process. 
The mast cell's role in the pathophysiology of the allergic inflammation has received 
increased interest during the last decade. This is due to new knowledge on the heterogeneity 
of the mast cells, their origin in the bone marrow and their differentiation. The fact that mast 
cells produce and secrete cytokines has given them a potential role in cell regulation, 
orchestrating an autoregulation of t he allergic inflammation. Furthermore, there has been an 
intense research on mast-cell derived mediators such as trvptase and chymase, two neutral 
esterases in the mast cell granule. 
The over-all aim of this study was to elucidate the role of the mast cell in allergic 
inflammation. To achieve this, clinical, morphological and biochemical studies have been 
performed, both as allergen challenges in the laboratory and under natural allergen exposure 
during the pollen season. 
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NASAL AIRWAYS 
The specialised anatomy of t he nose is important for its function: heating, humidification and 
filtration of inhaled air; the sense of smell; and conservation of exhaled water and heat in the 
relatively cold anterior part of the nose. The nasal mucosa constitutes the first line of defence 
for the body interior, having a high capacity to remove inhaled microorganisms, allergens and 
irritating substances. The efficacy of the nasal filter depends upon the size of the particles. 
Most particles larger than 10 |i.m (pollen grains) will be trapped in the nose, while most 
particles smaller than 2 |im (mould spores) pass through the nose. Deposited particles are 
cleared from the nose within 10-30 min by mucociliary transport (Mygind and Bisgaard 
1990). 
The vestibulum nasi is lined by skin. The nasal cavity is lined by a ciliated pseudostratified 
columnar epithelium consisting of nonciliated epithelial cells, ciliated epithelial cells (with 4-
6 |i.m long cilia), goblet cells and basal cells, all resting on a basement membrane. Beneath 
the basement membrane is the lamina propria, consisting of connective tissue, glands, blood 
vessels and nerves. Fibroblasts and macrophages form the most common cell types but 
varying numbers of leukocytes, lymphocytes, plasma cells, and mast cells are seen in the 
stroma (Petruson et al. 1984). The main constituent of nasal fluid is water (95-97%), but it 
also contains mucin (2.5-3%) and electrolytes (1-2%) as well as actively secreted IgA. Small 
molecules like histamine (mol wt 111 Da) readily penetrate the epithelial lining and small 
proteins (e.g allergens with a mol wt of 10,000 to 40,000 Da) from pollen grains may be 
soluble in the nasal surface liquid and may penetrate into the lamina propria to some extent 
(Okuda 1977). The wind-borne pollen grains (15-50 ^irn) p robably do not penetrate the 
epithelial lining (Okuda 1977, Wihl and Mygind 1977). 
The nasal cavity is richly supplied with blood that comes from branches of both the internal 
and the external carotid arteries. The mucosa has a well-developed capillary network. There 
is a subepithelial layer of capillaries, which have been shown to be partly of a fenestrated 
type (Cauna and Hinderer 1969). The cavernous sinusoids, which are especially abundant in 
the middle and inferior turbinates (Cauna 1982), are situated in the deepest parts of the 
lamina propria. A third functional and structural entity in the lower parts of the lamina 
propria is the arteriovenous anastomoses, which allow the blood to pass the capillary bed and 
are probably involved in thermoregulation (Cole 1982). The blood volume is regulated by the 
tone of the capacitance vessels (venous sinusoids and large veins), while the blood flow is 
regulated by the resistance vessels (small arteries and arterioli). The post-capillary venules 
are responsible for the inflammatory, mediator-induced increase in permeability of plasma 
proteins (Persson 1991). 
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The sensory nerve supply of the nasal cavities is derived from the ophthalmic and maxillary 
divisions of the trigeminal nerve. The non-myelinated nerve-endings are situated in the intra 
and subepithelial area (Cauna 1982). The sympathetic nerve fibres emerge from the stellate 
ganglion and mainly innervate the nasal mucosal vessels (Cauna 1982). The preganglionic 
transmitter substance is acetylcholine, which acts on nicotinic receptors, whereas the 
postganglionic transmitter is noradrenaline. Stimulation of a-adrenoceptors causes 
contraction of the vascular smooth muscles. The parasympathetic nerves originate in the 
superior salivatory nucleus. The transmitter is acetylcholine, which acts on nicotinic receptors 
preganglionically and muscarinic receptors postganglionically. Parasympathetic fibres are 
particularly numerous in the glands (Cauna et al. 1972) but the vessels are also innervated 
(Cauna 1982). Substance P, neurokinin A and K and calcitonin gene-related peptide are 
among a number of neuropeptides that are found in the autonomic and sensory nerve fibres of 
the airways in man. They are believed to participate in local axon reflexes upon stimulation 
of the nerve endings. 
Figure 1. Illustration of the nasal mucosa. Mucus covers the sutface of the pseudostratified 
epithelium. Ciliated cells, non-ciliated cells, goblet cells, and basal cells rest on the basement 
membrene. Fibroblasts, macrophages, leukocytes, lymphocytes, plasma cells, and mast cells 
are seen in the stroma between seromucous glands and capillaries. Adapted from Petruson et 
al. (1984). 
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ALLERGIC INFLAMMATION 
Inflammatory reaction 
Inflammation is the response of vascularised tissue to injury and is usually beneficial since it 
serves to resolve and repair the effect of damage. The factors that initiate inflammation are 
diverse and include infectious agents (bacteria, viruses and parasites), chemical agents (drugs, 
toxins and industrial agents), mechanical and ischemic injury, and immunological reactions, 
such as allergy and autoimmunity. The histopathological features of inflammation consist of 
changes in blood flow and caliber of small blood vessels and an increase in vascular 
permeability, the formation of an inflammatory exudate, and the escape of leukocytes from 
the blood into the extravascular spaces. This acute phase is followed by infiltration of 
lymphocytes and monocytes/macrophages together with proliferation of blood vessels and 
connective tissue. The memory capabilities of the immune system are conveyed by 
lymphocytes, but a specialised biological amplification system involving cellular and 
humoral components is necessary for host defence. The clearest example of the cells and 
mediators of the allergic response participating in host defence is the protective role of IgE, 
mast cells, basophils and eosinophils in helminth infection (Lee et al. 1986, Taverne 1989). 
When an adaptive immune response occurs in an exaggerated or inappropriate form causing 
tissue damage, the term hypersensitivity is applied. Coombs and Gell have classified 
hypersensitivity reactions into four types according to symptom pattern (Coombs and Gell 
1968). Type I, or immediate hypersensitivity, is dependent on the specific triggering of IgE-
sensitised mast cells by antigen resulting in the release of pharmacological mediators of 
inflammation. The allergic reaction has also been classified into immediate, late and delayed 
reaction, according to the time of onset of symptoms. Considering the complexity of the 
immune response, such classifications can at most be a useful over-simplification and it is 
now evident that allergy is an inflammatory response involving all cellular elements of the 
immune system. 
IgE 
The characteristic feature of allergic inflammation is the exaggerated IgE response, directed 
against innocuous antigens such as pollen. Following the initial contact of allergen with the 
mucosa there is a complex series of events before IgE is produced and before allergic 
symptoms result after a second contact with the same allergen. IgE production by B cells 
involves antigen presentation via antigen-presenting cells, T cell help and IL-4 stimulation of 
B cells to become IgE-producing. Different types of receptors for IgE have been described, a 
high-affinity IgE-receptor (FcEl-R), classically described on mast cells and basophils, and a 
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low-affinity IgE-receptor (FcElI-R), found on a variety of cells including lymphocytes, 
eosinophils, macrophages and thrombocytes, reviewed by Siraganian (1993). 
Mast cells 
Mast cells are found in loose connective tissue of most organs, except the brain, and are 
predominant in skin, airways and the gastro-intestinal tract. Mast cells exhibit a diversity of 
histological, biochemical and functional properties (Enerbäck et al. 1989). The role of mast 
cells in humans under non-pathological conditions is unknown but recent evidence of their 
cytokine production indicates that they may have a function in the growth and development 
of other cells (cf. Schwartz and Huff 1993). Mast cells are found in increased numbers in 
many pathological disorders such as allergic asthma (Gibson et al. 1993), allergic rhino-
conjunctivitis, atopic dermatitis, parasitic infection, mastocytosis, arthritis, scleroderma and 
fibrosis (Schwartz and Huff 1993). With IgE on its surface the mast cell is the primay effector 
cell in allergic diseases in mucous membranes. The contact between the allergen and the mast 
cells is enhanced by an allergen induced redistribution of the cells from the stroma to the 
epithelium (Enerbäck et al. 1986a, Enerbäck et al. 1986b). Situated superficially in the 
respiratory epithelium, the mast cell is ideally located to respond to inhaled allergen. By 
cross-linking of adjacent IgE-molecules on the mast cell surface, the allergen triggers the cell 
to degranulate. Upon stimulation, mast cells release a spectrum of preformed and newly 
formed membrane-derived mediators (See Figure 2). 
Mast cells are derived from pluripotential haematopoietic stem cells (Schwartz and Huff 
1993). They undergo only part of their differentiation in bone marrow and complete there 
differentiation in peripheral tissue microenvironments rich in fibroblasts or stromal cells. For 
humans it is not clear which cytokines stimulate mast cell maturation and development. The 
first mast-cell-specific marker detected on the mast cell precursors is Kit, a receptor tyrosine 
kinase highly expressed on mast cells (Galli et al. 1992). Kit+, IL-3" progenitors are thought 
to be released from the bone marrow and their further development is dependent on stem cell 
factor (SCF), the ligand for the Kit, found on fibroblasts (Irani et al. 1992, Agis et al. 1993). 
Recent studies show that IL-3 does not enhance maturation of SCF-dependent fetal liver mast 
cells and when cultured with SCF and IL-4, a marked inhibition of mast cell differentiation 
was seen (Nilsson et al. 1993). 
Morphology 
Mature human tissue mast cells are usually 9 to 12 |im in diameter and can be round, spindle-
shaped, or spider-like in shape and up to 20 jim long. Mast cell nuclei are rather long 
unsegmented ovals, and eccentrically placed, and rarely show mitotic figures in t issue (Galli 
1984). There are thin elongated folds of their plasma membrane and cytoplasmic filaments 
and lipid bodies are found. As in b asophils, free and membrane-bound ribosomes, and Golgi 
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structures are diminished in mast cells compare with other cells. Mast cells have numerous 
cytoplasmic granules (about 200), which vary remarkably in their shape and ultrastructural 
patterns. The granules can be filled with scrolls, crystals, particles, in reticular patterns or 
combinations of these patterns (Dvorak et al. 1983a, Enerbäck et al. 1986b). When stimulated 
in vitro, human mast cells undergo complex intracytoplasmic changes. Numerous 
degranulation channels are formed and granule matrix materials are solubilised prior to the 
development of multiple openings to the exterior of the degranulation channels (Dvorak et al. 
1983b). 
Different types of mast cells 
Mast cells of two major types have emerged as a consistent observation in human and rodent 
tissues. Recognition of this complexity is crucial for an understanding of mast cell biology 
and, potentially, for treating mast-cell-associated disease. It has been recognised for many 
years that mast cell populations in both humans and rodents differ in their ability to be 
identified using standard metachromatic dyes such as toluidine blue following formaldehyde 
fixation (Enerbäck 1966b, Pipkorn et al. 1988c). While in the rat intestinal mucosa the entire 
mast cell population is "formalin sensitive", there are a number of other differences between 
mast cells in specific tissue sites. Several nomenclatures are used to describe particular mast 
cell types. However, none of these is optimal, because the nomenclature does not relate to 
known functional differences between the different cell types. 
In rodents, mucosal mast cells (MMC) and connective tissue mast cells (CTMC) are the 
terms currently in most common use (Enerbäck 1966b). These mast cell types have been 
discriminated from one another based on proteoglycan content, neutral protease expression, 
arachidonic acid metabolites, and surface antigenic determinants (Schwartz and Huff 1993). 
The MMC lose their metachromatic staining property after treatment with s trong aldehyde 
fixatives (Enerbäck 1966b). The proteoglycan in CTMC is heparin while MMC have 
chondroitin sulphates (Yurt et al. 1977, Kusche et al. 1988). The content of neutra l protease 
in the granules qualitatively appears to distinguish rat CTMC, which contain chymase I and 
carboxypeptidase A, from rat MMC, which contain chymase II (Gibson and Miller 1986). 
In humans, subsets of mast cells have been identified based on similar staining characteristics 
which depend upon mast cell proteoglycan content (Pipkorn et al. 1988c). Schwartz and 
coworkers have defined mast cells in man in terms of their content of specific protease 
enzymes. The term tryptase positive mast cells (MCT) is used for cells with tryptase alone, 
and the term tryptase and chymase positive mast cells (MCTC) for those cells which contain 
both tryptase and chymase (Irani et al. 1986b). MCr have been described as the predominant 
population in the in testinal and respiratory mucosa while MCTC predominate the skin and 
some other sites (Irani et al. 1986a, Irani et al. 1986b). The consequences of the lack of 
chymase in the MCT cells are not known. 
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Histamine 
Histamine, ß-imidazolethylamine (mol wt 111 Da) is an intracellular mediator exerting potent 
effects on various target tissues. It is produced by decarboxylation of histidine. U biquitously 
distributed in mammalian tissues, histamine acting on histamine H \ and H2-receptors has a 
wide range of functions and is one of the major mediators of immediate hypersensitivity 
(Siraganian 1982, Wasserman 1983, Schwartz 1987). Histamine is also an important mediator 
in the central nervous system and the gastric mucosa (Sandvik et al. 1987). Stored in large 
amounts in metachromatic granules of mast ce lls and basophils, it is spontaneously released 
at low levels and actively released from these cells after challenge with allergens to which the 
allergic patient is sensitised, or with "non-specific" histamine releasers such as substance P, 
polyamines, opiates and a range of lymphokines and cytokines. As an extrac ellular mediator, 
histamine functions as a local hormone that is rapidly metabolised by either of two enzym atic 
pathways, methylation (70%) by histamine N-methyltransferase, or oxidation (30%) (Holgate 
et al. 1993). 
Neutral proteases 
Mast cell neutral proteases are a unique series of proteolytic en zymes that comprise most of 
the protein of the mast cell granule. The biological importance of th ese enzymes is not yet 
determined but studies demonstrate that they are a heterogeneous population giving a basis 
for a mast cell classification according to the neutral protease content (Irani et al. 1986a, Irani 
et al. 1986b). 
Trvptase was the first neutral protease to be identified in human mast cells (Glenner and 
Cohen 1960). Human tryptase is a tetramer with a molecular weight of 134 kDa, composed of 
subunits of 31-35 kDa (Schwartz et al. 1981). Tryptase is contained in all mast cells, it 
constitutes approximately 20% of the total cellular protein content and is stored within the 
secretory granules in association with heparin proteoglycan. In MCT cells levels of tryptase 
are around 10 pg per cell and in MCJC cells they are up to 35 pg per cell (Schwartz et al. 
1987). Very small quantities of tryptase, around 0.04 pg per cell, are found in human 
basophils (Castells et al. 1987). When the mast cell is stimulated for exocytosis, tryptase is 
released into the extracellular enviroment. After anaphylactic reactions, human tryptase 
diffuses into the systemic circulation and can be quantitated by serum immunoassay 
(Schwartz et al. 1987, Schwartz et al. 1989). Tryptase, in the absence of he parin, has a very 
short half-life of ac tivity (Schwartz and Bradford 1986). Since the proteoglycans are large 
molecules and would be predicted to diffuse poorly, substantial tryptase activity is th ought to 
be limited to the local area of mast cell activation. There is no known major biological 
function of this enzyme. Potential biological properties are fibrinogenolysis, high molecular 
weight kininogen destruction, prostromelysin activation, cleavage of C3 to C3a and 
neuropeptide degradation (cf. Holgate et al. 1993). 
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Chymase (mol wt 30 kDa) is a family of enzymes with chymotrypsin-like activity (Schechter 
et al. 1986). While being demonstrable only in certain subpopulations of higher mammalian 
mast cells (MCpC )• chymases are the dominant protease in rodent mast cells (Gibson and 
Miller 1986). Chymase is a monomer, stored active, presumably bound to heparin and 
secreted with histamine. It converts angiotensin I to angiotensin II approximately four times 
more efficiently than does angiotensin converting enzyme (ACE) (Reiley et ai. 1982, 
Wintroub et al. 1984). Chymase also inactivates bradykinin and attacks the lamina lucida of 
the basement membrane at the dermal-epidermal junction of human skin. Its activity is 
inhibited by several biological inhibitors (Holgate et al. 1993). 
Carboxypeptidase enzymes are the most recent enzymes to be localised to and purified from 
human mast cells. In man it has been found in MCjC-cells and has similar activity as 
chymase but closely associated with the heparin proteoglycan, which in tu rn largely remains 
bound to the extracellular surface of the mast cell after degranulation (Goldstein et al. 1989). 
Other enzymes and chemotactic factors 
Mast cells also contain different acid hydrolases and oxidative enzymes as well as 
chemotactic factors like eosinophil chemotactic factor of anaphylaxis (ECF-A) and neutrophil 
chemotactic factor of anaphylaxis (NCF-A) (Holgate et al. 1993). 
Proteoglycans 
Proteoglycans comprise a central protein core from which long carbohydrate side chains issue 
radially, giving the proteoglycan its characteristic physiochemical properties. Intracellular 
proteoglycans form the structural basis of lysosomal granules into which the Golgi apparatus 
secretes various other chemical substances pertinent to the cell's function. The proteoglycan 
content of cells varies between different cell types and species. The proteoglycan in human 
mast cells is heparin (60 kDa). Histamine is bound to the carboxyl groups of glucuronic and 
iduronic acid, whereas the neutral proteases are bound to the anionic carboxyl and sulphate 
groups of the glycosaminoglycans. Heparin acts as an anticoagulant by enhancing the ability 
of antithrombin 3 to inhibit the proteases involved in the coagulation cascade. (Holgate et al. 
1993). 
Cytokines 
Numerous studies have demonstrated that immunological activation of m urine bone-marrow-
cultured mast cells can lead to the expression of a number of cytokines (Gordon et al. 1990, 
Galli et al. 1991). These include IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, granulocyte/macrophage 
colony stimulating factor (GM-CSF) and tumour necrosis factor (TNF)-a. The production of 
cytokines by human mast cells has not been as extensively studied as the murine counterpart, 
but several studies have appeared which suggest a similar pattern in humans. For example, 
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human lung and skin mast cells have been shown to produce TNF-a (Walsh et al. 1991, 
Ohkawara et al. 1992). Human mast cells have also been shown to produce IL-4, IL-5 and IL-
6 (Bradding et al. 1991). Although the significance of IL production by hu man mast cells is 
not known, the fact stands that thay produce and secrete cytokines. This gives the mast cell a 
potential role in cell regulation, the possibility of orchestrating an autoregulation of the 
allergic inflammation (See Figure 2). 
Newly generated mediators 
Diverse products of the complex pathways of oxidative metabolism of arachidonic acid are 
potent mediators of a wide range of physiological and pathological processes in humans, see 
Table 1. 
Mediator Pharmacological actions  
PGD2 Bronchoconstrictor; peripheral vasodilator; coronary and pulmonary 
vasoconstrictor; inhibition of platelet aggregation; neutrophil chemo-attractant; 
augmentation of b asophil histamine release. 
PGF2 Bronchoconstrictor; peripheral vasodilatator; coronary vasoconstrictor; inhibitor of 
platelet aggregation. 
TXA2 Vasoconstrictor; aggregates platelets; bronchoconstrictor. 
LTB4 Neutrophil Chemotaxis; adherence and degranulation; augmentation of vascular 
permeability. 
LTC4 Bronchoconstrictor; increases vascular permeability; arteriolar constrictor. 
LTD4 Bronchoconstrictor; increases vascular permeability. 
LTE4 Weak bronchoconstrictor; enhances bronchial responsiveness; increases vascular 
permeability. 
PAF Aggregates platelets; Chemotaxis and degranulation of eosinophils and neutrophils; 
increases vascular permeability; bronchoconstrictor; hypotensive.  
Table 1. Pharmacologic activities of newly generated mediators (From Holgate et al. 1993). 
Cyclooxygenase is associated with the endoplasmic reticulum of most cells. It catalyses the 
incorporation of molecular oxygen into the arachidonic acid molecule and promotes ring 
closure to form unstable intermediates that are converted to the different prostaglandins 
(PGD2, PGE2 and PGF2), prostacyclin (PGI2) and thromboxane A2 (TXA2). Arachidonic 
acid may also be metabolised by a variety of lipoxygenase enzymes. The 5-lipoxygenase 
pathway gives rise to the leukotrienes (LTB4i LTC4> LTD4 and LTE4). Together LTC4, 
LTD4 and LTE4 comprise slow reacting substances of anaphylaxis (SRS-A). Platelet-
activating factor (PAF), a phospholipid, is stucturally different from the arachidonic acid-
derived products but is also synthesised, from an inactive precursor, upon activation of 
phospholipase A2 (Holgate et al. 1993). 
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Figure 2. Schematic presentation of the role of the mast cell in acute and chronic allergic 
inflammation (Adapted from Holgate et al. 1993). 
Basophil granulocytes 
Basophil granulocytes are normally found in very small numbers in the circulation. They 
have been implicated in the allergic inflammation of mucosal membranes, especially the nose 
(Schleimer et al. 1985). The mast cell and the basophil granulocyte share many properties but 
the relationship between these two cell types is unclear. Basophils differentiate from 
pluripotent stem cells and IL-3 has been consistently found to stimulate the growth of 
basophils (Saito et al. 1988). Besides IL-3, GM-CSF also induces basophilic differentiation 
along with other cells of granulocytic lineages such as eosinophils. Mature human basophils 
are usually small round cells 5 to 7 |im in diameter. They have short surface processes and 
many, large cytoplasmic granules that contain electron-dense particles, and, rarely, large 
crystals on electron microscopy. The granules are basophilic on routine laboratory staining 
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(Giemsa, Wright's), as well as with specific stains such as toluidine blue and alcian blue. The 
nucleus is segmented, usually bilobular, and the chromatin is heavily condensed. 
Endoplasmic reticulum and Golgi apparatus are inconspicuous. Upon activation individual 
granules of basophils fuse with the cell membrane and release their content extracellularly 
(Dvorak et al. 1983a, Dvorak et al. 1983b). The granules contain histamine and chondroitin 
sulpfate À and a small amount of tryptase (Castells et al. 1987). Furthermore, basophils 
produce LTC4 but not PGD2 (Schwartz and Huff 1993). 
Metachromatic cells in the nasal mucosa 
Cells with basophil, metachromatic granules have been repeatedly observed in the nasal 
epithelium and on the mucosal surface in patients with allergic rhinitis. This was first 
described by Bryan and Bryan (1959). Okuda interpreted the intraepithelial cells as mast cells 
but described another cell in the mucous blanket as basophils (Okuda et al. 1983, Okuda et al. 
1985). Since then, metachromatic cells in the nasal mucosa have variously been addressed as 
basophils or mast cells (Davies et al. 1987, Bascom et al. 1988, Liu 1988, Pipkorn et al. 
1988b, Pipkorn et al. 1989). The presence of highly sulphated proteoglycans in secretory 
granules of mast cells and basophils results in metachromasia when these cells are stained 
with basic dyes. These staining techniques reflect the structral properties of the proteoglycan 
core of the granules, especially the glycosaminoglycan composition. Staining with toluidine 
blue results in a shift in the absorbtion spectra of the dye to a shorter wavelength giving the 
metachromacy, a change in the color from blue toward violet (Enerbäck 1986). The 
morphological criteria for the identification of mature and immature basophils and mast cells 
are related to the function of the cells. Expressions of activation and release reaction may alter 
the morphology of basophils and mast cells under basal conditions, and as a result may create 
confusion in the identification of these cells. Until a specific marker for mast cells as well as 
basophils is found, the different metachromatic cells cannot be classified without 
reservations. The mast cell is traditionally identified by the metachromasia of its secretory 
granules (Ehrlich 1879, Enerbäck and Norrby 1989). The mast cell can also be identified 
using anti-IgE-antibodies (Callerame and Condemi 1974, Feltkamp-Vroom et al. 1975, 
Stallman et al. 1977, Rognum and Brandtzaeg 1989, Bachert et al. 1990) and anti-tryptase-
antibodies (Schwartz 1985). Basophils contain metachromatic granules, histamine and high-
affinity IgE receptors (Ishizaka et al. 1970) but only a minimal amount of tryptase (Castells et 
al. 1987), suggesting that this enzyme can be used as a selective marker for the tissue mast 
cell (Irani et al. 1986b). In a recent report, metachromatic cells recovered from nasal lavage 
fluid after allergen challenge have been found to carry CD 18, a typical leukocyte marker, 
indicating a basophil lineage (Iliopoulos et al. 1992). 
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Eosinophil granulocytes 
The eosinophil granulocyte is a bone-marrow-derived, cytotoxic cell which usually presents 
in low number in human peripheral blood with the exception of allergic, parasitic and some 
uncommon diseases such as the idiopathic hypereosinophilic syndrome, in which it is 
commonly found in increased numbers both in peripheral blood and in affected tissues. IL-3 
promotes eosinophil differentiation of pluripotent stem cells. IL-5 induces selective 
differentiation and proliferation of eosi nophils, and activation synergistically enhanced by 
GM-CSF. PAF is the strongest among a group of known eosinophil chemotactic factors. 
Since its discovery in Paul Ehrlich (1879), a role for the eosinophil granulocyte in the defence 
against parasites has been proposed by several investigators. The role played by the 
eosinophil in this defence has remained enigmatic, however, although direct killing of the 
parasite by the eosinophil has been suggested. The proposed capacity to kill parasites would 
imply that the eos inophil is capable of tissue destruction and this putative destructive ability 
might in some situations also be turned against the host, for instance in asthma. The protein 
content of the human eosinophil granules is dominated by the presence of four major proteins 
as depicted in Table 2. These proteins have high iso electric points, for some of them above 
pH 11, and have been shown in vitro to ki ll parasites such as Schistosoma mansoni, 
Trichinella spiralis and Trypanosoma cruzi. 
Protein Molecular weight (kDa) 
Eosinophil cationic protein (ECP) 18.5-22 
Eosinophil peroxidase (EPO) 67 
Eosinophil protein-X (EPX) or eosinophil derived neurotoxin (EDN) 23 
Major basic protein (MBP) 92 
Table 2. The major proteins of human eosinophil granules (From Venge and Peterson 1989). 
Two populations of granules can be distinguished morphologically in human eosinophils. 
One is the large, crystalloid-containing population which is also peroxidase positive and the 
other is made up of small peroxidase-negative granules. The crystalloid structure is made up 
of ma jor basic protein (MBP). Depending on the type of s timuli and activation stage of th e 
cell, the granule proteins may be released selectively, although they are contained in the same 
granule population. Eosinophils produce LT< V, and LT D4 and studies indicate that they also 
produce cytokines such as IL-3, GM-CSF and transforming growth factor (TGF)-a and ß, a 
multifactoral regulator of cell growth and associated with diseases characterised by fibrosis as 
reviewed by Venge and Peterson (1989) and Suret al. (1993). 
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T-he!per cells 
Two sub-populations of T-helper lymphocytes (CD4+ cells) have been described, with 
distinct cytokine profiles (Mosmann et al. 1986). The characteristic cytokines of the first 
group (TH1 cells) are IL-2 and IFN-y and the second group (TH2 cells) produce IL-4, IL-5, 
1L-6 and IL-10. Both cell types secrete 1L-3 and GM-CSF (Mossrnan and Moore 1991). 
Isolated T-cell clones specific for allergens produce TH2-cell cytokine profile whereas T-cell 
clones specific for purified protein derivative (PPD) of Mycobacterium tuberculosis produce 
THl-cell cytokines. T lymphocytes from asthmatic patients bear the receptor for IL-2, a 
phenotypic sign of activation (Azzawi et al. 1990). In broncheoalveolar lavage fluid from 
patients with atopic asthma, there is a predominance of TH2 cells (Robinson et al. 1992). 
There is an increase in the expression of messenger RNA for the TH2 cytokines after nasal 
allergen provocation (Durham et al. 1992). As i llustrated in Figure 3, the interleukines of 
TH2 cells promote allergic inflammation: IL-3 promotes eosinophil and basophil growth and 
differention; IL-4 stimulate B cell proliferation and IgE production, and favour mast cell 
activation; and IL-5 enhance eosinophil differentiation, vascular adhesion and survival. The 
two T helper cell subgroups have opposite effects on IgE production, as IL-4 and IL-6 
stimulate and INF-f suppress IgE production of B cells. Furthermore, IL-10 suppress the 
development of TH1 cells (Mosmann 1991). Because of these functional characteristics, TH2 
cells are strongly implicated in the pathogenesis of allergic inflammation but TH1 cells in 
delayed-type hypersensitivity reactions (Del-Prete 1992, Corrigan and Kay 1993). 
Mediators of 
inflammation 
Normal Eosinophil 
Atopic 
Figure 3 Schematic presentation of the "TH1 - TH2" theory. Ag = allergen; APC = antigen 
presenting cell; MHCII = major histocompatibility complex II; see text. 
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Adhesion molecules 
Cell trafic is controlled by adhesion molecules, expressed on all s urfaces that allow cell-to-
cell contact. These glycoproteins have a variety of functions, which include promoting 
adhesion of one cell to another or to a tissue matrix, activating cells and promoting cellular 
migration and infiltration. Human sensitised pulmonary endothelial cells increase 
intercellular adhesion molecule (ICAM)-l expression after allergen challenge (Gibson et al. 
1991). ICAM-1 promotes recruitment of eosinophils and lymphocytes. Human basophils 
express ICAM-1, but mast cells express it to a much lesser degree (Valent and Bettelheim 
1992). The vascular cell adhesion molecule (VCAM)-l promotes adhesion of lymphocytes, 
monocytes, eosinophils, and basophils to endothelium. The expression of VCAM-1 is 
induced by IL-4 which thereby selectively recruits eosinophils, basophils and possibly mast 
cells but not neutrophils to the allergic inflammation (Schleimer et al. 1992). On the other 
hand, an endothelial cell adhesion molecule (ELAM)-l, expressed by TNF-a -stimulated 
endothelial cells, promotes neutrophil adhesion and migration. Endothelial cells express E-
selectin after degranulation of human mast cells (Matis et al. 1990). Thus, a role for human 
mast cells as "gatekeepers" of the endothelium is established and indicates that mast cell 
mediators other than amines can influence endothelium in the inflammatory process. 
(Reviewed by Calderon and Lockey 1992) 
Allergic rhinitis 
Most patients develop allergic rhinitis during childhood and young adulthood. The pattern of 
the disease is determined in part by the spectrum of sensitivities exhibited by the patient. 
Thus, the most common symptom complex involves seasonal allergies were exacerbations 
correspond to the pollinating seasons of the trees in early spring, grasses in late spring and 
early summer and weeds in late summer to early autum. Conversely, year-round allergens 
such as dust mites and animal emanations can cause perennial symptoms. The allergic 
response in the nasal mucosa comprises: episodic sneezing, itching, rhinorrhea, and nasal 
congestion. Associated symptoms include palatal and eye itching, conjunctival swelling, 
post-nasal drip, coughing, and the irrepressible need to sneeze. The symptoms of allergic 
rhinitis are caused by the following processes: 1) Vasodilatation causes mucosal swelling and 
increased vascular permeability causes oedema fluid to collect in the mucosa, causing nasal 
congestion and also contributing to the secretions in the nasal lumen. Decreased vascular tone 
and increased permeability are caused by the actions of vasoactive amines including 
histamine, prostaglandins and leukotrienes, bradykinin and PAF, and secondarily by the 
release of neuropeptides on the endothelial cells in t he superficial post-capillary venules. 2) 
Mucous secretion contributes to host-defence functions of the secretions. Glands are 
stimulated directly by prostaglandins, and reflexly by histamine. 3) Neural reflexes stimulated 
by histamine and possibly by other mast cell mediators cause the pruritus and sneezing 
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reflexes, as well as glandular secretion. 4) Late-phase reactions contribute to the oedema and 
irritability of the nose. Late-phase reactions are caused by inflammatory factors released from 
mast cells and include chemotactic factors, PAF, eicosanoids, and a number of in flammatory 
cytokines which are also synthesised and released by lymphocytes. These factors lead to the 
expression of adhesion molecules, the attraction of infla mmatory cells and the infiltration of 
the mucosa with neutrophils, eosinophils, basophils, thrombocytes, lymphocytes, 
macrophages, and mast cells. This inflammation plays a major role in the increased irritability 
of the nose characteristically seen during the allergy season. The spectrum of symptoms of 
allergic rhinitis is therefore caused by both acute and chronic events as reviewed by Kaliner 
(1993). 
Treating allergic rhinitis 
After a diagnosis is established, the most important thing is to inform the patient about the 
nature of the disease. Elimination of the offending agent is of course the most adequate 
measure, but when environmental control cannot be accomplished symptomatic 
pharmacological treatment tends to be the treatment of first choice. Immunotherapy is most 
effective in young monoallergic patients but has for several reasons mostly been used in 
severe cases where pharmacological treatment has not given the expected results. The 
immunomodulation shifts the T-helper cell reaction towards the THl-like spectrum of 
cytokines where IFNy has its negative effect on the IgE-production of the B-cell (Durham 
1993). The possibility of potential benefits of surgical intervention should be considered for 
every patient. Pharmaceutical t reatment is aimed at two targets, preventing or reversing the 
acute events and preventing the late responses which cause the chronic inflammatory 
changes. Sodium cromoglycate is a widely used antiallergic drug that is thought to "stabilise" 
mast cells and prevent exocytosis (Leung et al. 1988). Antihistamines are competitive 
inhibitors acting on the H j-receptor with high affinity. Their direct antiallergic action has 
recently been reviewed by Simons and Simons (1993). Only glucocorticoids will be 
discussed in more detail here. 
Glucocorticoid effects 
Glucocorticoids are widely used in the treatment of rhinitis. They have been found to 
decrease the symptoms that arise immediately after allergen provocation. The nasal symptoms 
occurring 2 - 11 h after allergen provocation can be completely eliminated by topical 
pretreatment with corticosteroids (Reviewed by Mygind 1993). Corticosteroids have a 
multitude of actions that may be potentially beneficial in allergic airway diseases. They 
decrease inflammatory cell recruitment and activation (Schleimer 1990), upregulate ß2 
receptors (Svedmyr 1990) and decrease microvascular permeability (Williams and Yardwood 
1990) and they may decrease mucus production (Lundgren et al. 1990). in terms of molecular 
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mechanism, steroids aie thought to act by b inding to a glucocorticoid intracellular receptor, 
which is then activated and binds to the cell nucleus, on to the regulatory glucocorticoid 
receptor elements associated with several genes (Munck et al. 1990). These glucocorticoid 
response elements then up or down regulate production of m essenger RNA unRNA), which 
eventually leads to increases or decreases in protein production. The proteins affected include 
enzymes and cell surface receptors. Such a mechanism of action, with gene regulation and 
then protein synthesis, will probably take some hours or even days to produce a clinical 
effect. Since glucocorticoids dramatically reduce allergic inflammation (Pipkorn et al. 1987a, 
Pipkorn et al. 1987b, Andersson et al. 1988, Gomez et al. 1988, Waiden et al. 1988, Bisgaard 
et al. 1990, Burke et al. 1992), their impact on mast cells has been of considerable interest. 
Their ability to alter transcription of a family of g enes is well k nown, but their role in IgE-
receptor-mediated activation of mast cells and basophils remains controversial (cf. Schleimer 
1993). Although in vivo experimental models demonstrate a reduced anaphylactic activity as 
the result of prior therapy with glucocorticoids, in vitro studies on mast cells have been less 
convincing (Cohan et al. 1989). 
Monitoring the inflammatory reaction in the human nasal mucosa 
As yet, there is no single parameter which can be used to measure the severity of the 
inflammatory reaction in the airway mucosa. The symptoms experienced in allergic 
inflammatory nasal disease can all be results of disorders not regarded as inflammatory 
reactions. The mere presence of inflammatory cells (neutrophils, eosinophils, mast cells, 
platelets, lymphocytes and basophils) and their products in and/or on the nasal mucosa may 
not be equal to inflammation. The cells may be present without affecting the tissue, or rather 
in order to fulfil tissue repair. It is only when it can be ascertained that the cells are activated 
and actively contribute to the inflammatory reaction that they may define airway 
inflammation and symptoms. Even so, the relationship between cell numbers and the degree 
of inflammation is uncertain. A series of diagnostic modalities can help to study nasal 
disorders. These include history, physical examination, rhinoscopy, rhinomanometry, 
acoustic rhinometry, rhinostereometry, nasal challenges, biochemical determinations, 
immunology studies, in vivo and in vitro testing for specific IgE, imaging, blood flow and 
ciliary function analysis, and examination of nasal morphology. The selection of sampling 
method for morphological and biochemical studies depends on the aims of the study. Some of 
the considerations are: the age of the patient, the need for repeated sampling, the site and 
thickness of the nasal mucosa, and the requirement for simultaneous biochemical and 
morphological studies. Thus, a number of methods have evolved, such as blown secretions, 
smears taken with cotton wool swabs, imprints, brushing, nasal scrapings, nasal lavages and 
biopsy, each method having its pros and cons (Pipkorn and Karlsson 1988). 
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AIMS OF THE INVESTIGATION 
The purpose of this study was to evaluate: 
• the correlation between the mast cell, its mediators and allergic symptoms (I - IV) 
• the cellular kinetics after allergen challenge and during natural pollen exposure (I, II, V) 
• the occurrence of the basophil granulocyte in allergic inflammation (II, V) 
• the effect of corticosteroid treatment on the mast cell and its mediators (IV, V) 
• the mast cell sub-populations in allergic inflammation (V). 
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MATERIAL AND METHODS 
Design of the Studies 
Study I. An allergen challenge was performed in ten asymptomatic patients with 
strictly seasonal allergic rhinitis. For comparison, seven nonallergics were challenged with 
allergen and seven allergies challenged with diluent. Cell samples, using the brash technique 
and nasal lavage were taken before challenge and at 2-hourly intervals during 12 h. The 
subjects rated their nasal symptoms before each sampling and 15 min after the challenge. The 
cell suspensions were cytocentrifuged onto microscope slides for enumeration of 
metachromatic cells in toluidine-blue-stained samples and differential counting of 
eosinophils, neutrophils and epithelial cells by light microscopy. Histamine was determined 
in the cell pellets. 
Study II. Nasal brush and lavage samples were obtained before a single nasal allergen 
challenge and every 2 h for 12 h after the challenge in 10 allergies and 3 controls. The 
subjects rated their nasal symptoms before each sampling and 15 min after the challenge. The 
total numbers of IgE-bearing and tryptase-containing cells and the histamine content of the 
cell pellets were studied in brush samples. Toluidine-blue-stained brush and lavage samples 
were used to differentiate the metachromatic cells into mast cells or basophils according to 
their morphology. 
Study III A nasal allergen challenge with 3 allergen doses was performed in 25 patients 
with strictly seasonal allergic rhinitis and 6 normal controls. A nasal lavage technique was 
used to monitor changes in local levels of tryptase, histamine and TAME-esterase activity. 
Study IV. Twenty-six patients with strictly seasonal allergic rhinitis entered a double-
blind, placebo-controlled, randomised, parallel group study of the effect of 4 weeks' 
treatment with topically-applied fluticasone propionate followed by a 4-week follow-up 
period. Allergen challenges with nasal lavages were performed before the start of the study 
and every second week for 8 weeks. The lavage fluid was analysed for histamine and tryptase 
levels and TAME-esterase activity. The patients were subjected to pretreatment nasal biopsy 
at a preparatory visit two weeks before the start of the study and post-treatment nasal biopsy 
directly after the allergen challenge after the treatment period. The biopsies were analysed for 
mast cell density and histamine content. 
Study V. Tne distribution and density of metachromatic cells and mast cells containing 
chymase plus tryptase (MCJC) or tryptase only (MCT) were studied in nasal mucosa using 
dye-binding techniques and immunohistochemistry. Biopsies were obtained from 17 subjects 
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with birch pollen allergy before the pollen season and during the season, and from 9 healthy 
controls. Six patients were treated with intranasal glucocorticosteroid before and during the 
season in an open study. 
Subjects 
Normal subjects 
A total of 22 healthy individuals participated in these studies. The subjects in Studies I and II 
were partly identical. They were all non-atopic subjects with no history of allergic disease, or 
of chronic or recurrent nasal diseases. Furthermore, they had no symptoms of acute airway 
disease at the time of the challenge procedure. No medication was allowed during the studies. 
(I, II, III, V) 
Allergic patients 
A total of 60 patients were recruited for these studies. The subjects in Studies I and II were 
partly identical as were the subjects in Studies III and IV. All patients had a history of 
seasonal allergic rhinitis due to birch or grass pollen, a positive skin prick test and a positive 
nasal provocation test to birch or timothy pollen. The subjects in Studies I and II had strictly 
grass pollen allergy. The subjects in Studies III and IV had birch and/or grass pollen allergy. 
The subjects in Study V had birch pollen or birch-and-grass pollen allergy. The exclusion 
criteria were nasal polyps, asthma, dermal manifestation of their atopic disease or pregnancy. 
No medication was allowed during the studies except for the study drugs in Studies IV and V. 
( I - V )  
Nasal allergen provocations 
Studies I - IV took place during pollen-free winter months and were designed as an open 
investigation regarding the challenge agents (Pipkorn et al. 1987). Both nasal cavities were 
challenged in Studies I and II, with either one spray of timothy pollen allergen extract, 
10,000 Biological Units (BU)/ml, or the diluent (Pharmalgen®, Pharmacia Diagnostics 
Norden AB, Uppsala, Sweden) from a metered dose pump delivering 0.13 ml in each 
actuation. A unilateral challenge procedure involving nasal lavages for the harvesting of 
mediators was used in Studies III and IV. The procedure started with 3 quick lavages with 10 
ml of saline, 5 ml into each nasal cavity, with the head tilted backwards during closure of the 
soft palate. Lavages were then performed at constant 10 min interval. Each of the lavages, 
starting with the fourth, was immediately followed by the administration of a challenge agent, 
the sequence being oxymetazoline, diluent, diluent, 100 BU/ml of allergen (birch or timothy), 
1,000 BU/ml and, finally, 10,000 BU/ml. Each lavage was designed to harvest the result of 
the preceding challenge (Naclerio et al. 1983). At each of 5 visits (study weeks 0 to 8) in 
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Study IV, unilateral nasal allergen challenges were performed on alternate sides, starting with 
the right side. The challenge procedure was the same as in Study III. The mechanical pump 
used for the challenges delivered 0.13 ml in each spray. 
Natural allergen exposure 
In Study V the subjects were observed for a period of 2-3 weeks into the pollen season until 
the patients had developed symptoms of their allergic disease and the daily pollen news 
reported moderate levels of birch pollen (Associate Professor Sven-Olof Strandhede, 
Department of Taxonomy, University of Göteborg, Sweden). 
Assessment of symptoms 
During the challenge procedures in Studies I to IV, the subjects continuously registered their 
nasal symptoms on a symptom chart using a 5-point scale: 0 = no, 1 = mild, 2 = moderate, 3 
= severe and 4 = intolerable symptoms. The symptoms recorded were nasal congestion, 
rhinorrhea and sneezing and in Studies III and IV nasal itching was also recorded. 
Furthermore, the number of sneezes was registered. A composite symptom score was 
calculated as the sum of the scores for each symptom. The sneeze score was calculated as 
follows: 0 sneezes = 0, 1 to 4 sneezes = 1, 5 to 9 sneezes = 2, 10 to 19 sneezes = 3 and 20 or 
more sneezes = 4. No systematic symptom assessment was made in Study V. 
Material sampling methods 
The nasal lavage method 
In Studies I and II the nasal lavage was performed using a compressible plastic container 
containing 12 ml of sterile saline with 0.1% of human serum albumin (Greiff et al. 1990). 
Both nasal cavities were lavaged twice. In Studies III and IV a nasal lavage provocation 
procedure was used as described above (Naclerio et al. 1983). 
The brush method 
In Studies I and II a 5.5 mm diameter nylon brush (Doft AB, Östhammar, Sweden), was used 
for cell sampling (Pipkorn et al. 1988a). The brush was placed between the nasal septum and 
the inferior turbinate and removed gently. No anaesthesia was used. The brush was then 
shaken vigorously in 2 ml of buffered salt solution and the cell suspension used for analysis. 
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Nasal biopsy 
In Studies IV and Study V nasal mucosal specimens were obtained after topical anaesthesia. 
A biopsy was performed 1 cm behind the anterior edge of the inferior turbinate using a pair of 
cup forceps (Pipkorn and Karlsson 1988). 
Analysis of biochemical markers 
TAME-esterase activity 
In Studies III and IV N-a-tosyl-L-arginine-methyl-ester-(TAME)-esterase activity, i.e. 
enzymes with arginine esterase activity, was measured in returned lavage fluid using a 
radiochemical method essentially as described by Imanari et al. (1976) and adapted for the 
nasal lavage procedure (Naclerio et al. 1983). The method is based on the enzymatic 
liberation of ^H-methanol from the synthetic substrate [^HJ-TAME. A 40 |ll aliquot of lavage 
sample and 10 |al of a 0.2 M Tris buffer, pH 8.0, were put into a 1.5 ml propylene microtube. 
The enzymatic reaction was then started by addition of 10 |ll of pHj-TAME; i.e. 0.38 x 10"4 
mg of [3H]-TAME. The microtube was placed in a counting vial containing 10 ml of 
Econofluor (a lipophilic scintillation solution) and 50 pi of the stop solution (1 vol. glacial 
acetic acid and 9 vol. 0.02 M TAME; i.e. 0.38 mg of TAME). The counting vial was capped, 
and after 1 hour at room temperature the reaction was terminated by shaking. The liberated 
^H-methanol was then partitioned into the lipophilic Econofluor solution, while TAME was 
dissolved in the hydrophilic suspension (mainly lavage sample and stop solution). The 
radioactivity in the lipophilic phase influenced the Econofluor solution to produce flashes, 
which were counted in a liquid scintillation spectrometer for 2 minutes. The activity was 
expressed as cpm (counts per minute). The enzymes which are active in this assay are 
designated TAME-esterases. All the samples from each person were assayed the same day. 
Tryptase 
In Studies III and IV tryptase in returned nasal lavage fluid was analysed using a 
radioimmunoassay on coated tubes (RIACT) with two monoclonal antibodies for tryptase 
(Wenzel et al. 1986, Enander et al. 1991). In the RIACT (Pharmacia Diagnostics AB, 
Uppsala, Sweden), 50 |il of nasal lavage fluid, 50 |il of sample diluent and 50 |il of 125i-
labelled anti-tryptase antibody were added simultaneously to plastic tubes coated with anti-
tryptase antibody. After incubation overnight, the tubes were washed three times and then 
counted in a gamma counter. The lower limit of detection for the assay is less than 0.5 ng/ml. 
The inter-assay coefficient of variation is 2.3% and the intra-assay coefficient of variation is 
2.8%. Recovery from spiked samples is 101.8% ± 7.4% (Enander et al. 1991). 
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Histamine 
HPLC 
In Studies I and I! cell pellets and in Study IV biopsies were analysed using highly purified 
liquid chromatography (HPLC). After thawing, the specimens were homogenised in 0.4 
molar perchloric acid followed by neutralisation of the extract with potassium carbonate with 
the precipitation of potassium Perchlorate. Histamine was purified by reverse-phase, high-
performance liquid chromatography using a C18 column with 15 mM citrate buffer at pH 3 
containing 5% methanol as a mobile phase and pentane sulphonic acid (5 mM) as the counter 
ion. Histamine was detected and assayed using a two-stage, post-column, derivative-forming 
procedure using o-phthalaldehyde as the fluorescent reagent (Alienmark et al. 1985). The 
limit of detection for the assay is 1 ng/ml. The intra-assay and interassay coefficient of 
variation for this method is less than 5%. The mean range of recovery in added samples is 
98% to 102%. 
RIA 
In Studies III and IV histamine in returned lavage fluid was determined by a solid-phase 
radioimmunoassay (RIA) (Morel and Delaage 1988, McBride and Kaliner 1989). In the RIA 
(Immunotech, Marseilles, France), succinyl glycin is used as a reagent to acylate histamine in 
the sample. The acylated histamine competes with 125I-labelled acylated histamine for the 
binding site of the monoclonal antibody. The limit of detection for the assay is 0.2 nM. The 
intra-assay and the interassay coefficient of variation for this method is less than 8% and 11% 
respectively. 
Morphological methods 
Fixation techniques 
The biopsy specimens in Study IV were fixed in Carnoy's fluid (60% absolute ethanol, 30% 
chlorophorm and 10% glacial acetic acid) for two hours followed by absolute ethanol for 12 
to 24 h. In Study V the biopsy specimens were fixed in iso-osmotic formaldehyde acetic acid 
(IFAA) (0.6% formaldehyde and 0.5% acetic acid in distilled water) for 12h followed by 12h 
in 70% ethanol. In Studies I and II cytological samples were air dried after 
cytocentrifugation. 
Staining techniques 
Dye binding procedures 
For staining of metachromatic cells in cytospin samples in Studies I and III and tissue 
sections in Studies IV and V, toluidine blue was used in a 0.5% aqueous solution at pH 0.5. 
The staining time was 30 min. The staining resulted in a violet-blue colour of the positively 
stained cells. In Study V the degree of aldehyde-induced blocking of cationic dye-binding 
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(Enerbäck et al. 1989) was assessed by counting the mast cells in serial sections fixed in 
IFAA and stained with toluidine blue for 30 min directly or after post fixation in 4% 
formaldehyde solution overnight and then stained for 30 min (Aldenborg and Enerbäck 
1988). Giemsa staining of cytospin preparations in Study I gave dark-blue nuclei of all cells, 
and highly red eosinophils. 
Immunohistochemistry 
In Study II the monoclonal anti-human-tryptase-antibody was used with the peroxidase-anti-
peroxidase (PAP) immunochemical technique to visualise tryptase-positive cells in cytos pin 
samples. Positively stained cells are brown. Specimens were counterstained with toluidine 
blue giving a faintly stained background. The monoclonal anti-human IgE and the alkaline 
phosphatase-anti-alkaline phosphatase (APAAP) immunochemical technique was used to 
visualise IgE-bearing cells in Study II. The method using Fast Red as the peroxidase substrate 
gives positively labelled red staining cells against the background, counterstained blue with 
hemalaun (Bachert et al. 1990). The immunofaistochemical double-labelling technique used 
on tissue sections in Study V results in a blue staining of M CT and brown coloured MCTC 
(Irani et al. 1986b). Mast cell chymase was visualised with the biotin-conjugated monoclonal 
anti-human-chymase antibody and the method gave a brown peroxidase reaction a s the end-
stage product. Tryptase was visualised by incubating the slides with the alkaline phosphatase-
conjugated mouse monoclonal anti-human mast cell tryptase antibody. A blue staining 
product was produced by incubating the slides with fast blue RR. Measures for negative and 
positive controls were included in the immunohistochemical staining procedures. 
Counting methods 
In Study I the total number of cells was e stimated by light microscopy and differential 
counting of eosinophils, neutrophils and epithelial cells was done on Giemsa-stained cytospin 
specimens. Furthermore, eosinophils were divided into non-vacuolated and vacuolated 
eosinophils, on the basis of the number of cytoplasmic vacuoles. In the toluidine-blue-stained 
cytospin specimens in Studies I and II, and the anti-tryptase and ant i-IgE-immunolabelled 
cytospin specimens in Study II, the total number of positively stained cel ls was counted on 
each specimen. Furthermore, in Study II, the metachromatic cells on toluidine-blue-stained 
cytospin specimens were assigned to four categories, "basophils", "mast cells", 
"unidentifiable cells" and "questionable metachromatic cells", based on morphological 
criteria (Bascom et al. 1988). In Studies IV and V, sections of biopsy samples were surveyed 
for immunopositive or metachromatic cells by light microscopy. In Study IV the cells and 
area of whole biopsy secti ons were surveyed. The epithelium and the subepithelial stroma 
was studied in Study V. Furthermore, the area surveyed for cell s was estimated. Biopsy cell 
counts were expressed as cells/mm2. Light microscopy was undertaken on coded specimens. 
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Investigational drugs 
Fluticasone propionate 
In Study IV 26 patients were randomly allocated to receive, under double-blind, parallell 
group conditions, fluticasone propionate aqueous nasal spray, 50 jig per actuation (13 
patients) or identical placebo (13 patients), two sprays into each nostril once daily for 4 
weeks. The total daily dose of fluticasone propionate was 200 |ig. The fluorinated, topically-
active glucocorticoid fluticasone propionate (Glaxo Laboratories Ltd., Greenford, Middlesex, 
England) has been shown to be safe and effective in the treatment of both seasonal and 
perennial rhinitis (Harding 1990, Banov et al. 1991, Nathan et al. 1991). 
Budesonide 
In Study V 6 patients were given nasal sprays containing budesonide. The dosage was 2 
actuations into each nostril morning and afternoon. Each actuation contained 50 (ig of 
budesonide, giving a total daily dose of 400 jig. The patients were instructed to start their 
treatment about 2 weeks before the expected start of the pollen season and then to continue 
until the second visit. Budesonide is a non-halogenated glucocorticoid with high local 
antiinflammatory activity and low systemic activity (Gruvstad and Bengtsson 1980, Gordon 
et al. 1987). Topically administered, the drug is effective in seasonal and perennial rhinitis 
(Day et al. 1990, Pedersen and Dahl 1990). 
Oxymetazoline chloride 
In Studies III and IV, oxymetazoline chloride, an a2-adrenoceptor agonist, was used 
topically. It was administered with a nasal mechanical spray pump delivering 100 (0.1 (two 
actuations of 50 (il) into each nasal cavity. The concentration used was 0.5 mg/ml, which is 
that recommended and clinically used for adults. 
Statistics 
The statistical evaluation was performed on a microcomputer using a statistical software 
package. In Study I, an analysis of variance (ANOVA) was used to evaluate whether 
observations made at the different times differed from one another. In Studies I, H, IV and 
Study V, Wilcoxon's signed rank sum test and Mann-Whitney's U test were used for 
nonparametric and in Study III, Student's t-test for parametric evaluation of changes within 
and between groups. In Studies I, II, IV and V, Spearman's correlation coefficient test and in 
Study III, regression analysis was used to evaluate correlation between the different 
observations, /-»-values of < 0.05 were considered significant. 
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RESULTS 
Study I. Mast cells and Eosinophils in the Allergic Mucosal Response to Allergen 
Challenge: Changes in Distribution and Signs of Activation in Relation to Symptoms 
The patients reacted promptly to the allergen challenge with an increase in nasal symptoms. 
In brush samples from the allergies challenged with allergen, the numbers of metachromatic 
cells increased to a maximum of 8-fold at 10 h. In the lavage specimens, no metachromatic 
cells were observed before provocation, but they progressively increased in number 2 to 12 h 
after provocation. Cell pellet histamine content decreased temporarily 2-4 h after challenge 
(p<0.05) in brush samples from allergen-challenged allergies. The local metachromatic cell 
density before challenge, as reflected in the brush specimens, correlated with nasal 
congestion, sneezing and the degree of eosinophilia. Three of the patients challenged with 
allergen differed from the remaining seven in that their brush samples obtained before 
allergen challenge contained a comparatively large number of metachromatic cells and 
eosinophils and they developed intense symptoms after challenge plus an intense eosinophil 
response after 4-10 h and a pronounced mast cell response 10-12 h after challenge. There was 
a temporary decrease in the histamine-per-cell ratio from those three patients with significant 
numbers of mast cells in the pre-challenge samples, as shown in Figure 4. 
6 8 10 12 Time (h) 
Allergen challenge 
Figure 4. The histamine content of metachromatic cells in the brush samples from the three 
patients that had high cell numbers in the pre-challenge brush samples. The histamine-per-
cell content is calculated from the number of metachromatic cells per slide and the histamine 
content of the cell pellets and corrected for volume of the sample. 
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Study II. Metachromatic, IgE-bearing and Tryptase-containing Cells on the Nasal 
Mucosal Surface in Provoked Allergic Rhinitis 
After an initial decrease at 2 h, the numbers of metachromatic, IgE-bearing and tryptase-
containing cells as well as the histamine content of the cells in the brush samples increased 
during the subsequent observation hours (Figure 5). The morphology of the metachromatic 
cells in the prechallenge brush samples agreed with that of mast cells but corresponded with 
mast cells and basophils in brush and lavage samples at 8 to 12 hours. There was a 
statistically significant correlation between all four parameters. There was a significant 
correlation between the cell numbers from all three staining methods as well as histamine 
values in pre-challenge samples and symptoms, expressed as numbers of sneezes 15 min after 
allergen challenge (n=10). 
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Figure 5. Combined graph showing means for four mast cell markers in brush samples from 
10 allergies challenged with allergen. Morphological data expressed as cells per slide (left 
side ordinate) and histamine concentration as nanograms per ml of re suspended cell pellets 
(right side ordinate). 
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Study III. Trj pta.se in Nasal Lavage Fluid after Local Allergen Challenge; Relationship 
to Histamine Levels and TAME-Esterase Activity 
The allergen challenge resulted in significant increases in the levels of all three markers, 
tryptase, histamine and TAME-esterase, following the allergen challenge. The increase in 
TAME-esterase activity as well as in the levels of tryptase was dose-dependent. A 3-fold 
increase in histamine was noted after the first allergen dose but no further rise was seen. In 
the individual measurements after the challenges there was a highly significant correlation 
between the TAME-esterase levels and the tryptase levels, while the generation of histamine 
and tryptase was not significantly correlated. On the other hand, when comparing the 
cumulative generation of the three markers, significant correlations were found between all 
three markers (Figure 6). Allergen challenges in 6 non-allergic controls did not result in any 
increase in tryptase levels. 
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Figure 6. Combined figure showing the relationships between the cumulative generation of 
histamine, tryptase and TAME in nasal lavage fluid after allergen challenge. Correlation 
coefficients (rs) and degree of statistical significance are shown (* = p<0.05, ** = p<0.01 ). 
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Study IV. Mast Cells and Mediators in the Nasal Mucosa after Allergen Challenge: 
Effects of Four Weeks' Treatment with Topical Glucocorticoid 
Treatment with fluticasone propionate did not influence mast-cell density, the tissue 
histamine concentration, the lavage histamine levels or the TAME-esterase activity, while a 
reduction in nasal symptoms and tryptase in nasal lavage fluid was revealed (Figure 7). 
The reaction to the allergen challenge in the untreated group was rather constant from one 
week to the other. There was a strong of positive correlation in the TAME-esterase activity 
and symptom score between the different weeks, as shown in Tables 2. 
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Figure 7. Graph showing tryptase levels (mean ± SEM) in returned lavage fluid from the 
actively treated group (n = 12) before (week 0) and after the treatment period (week 4) 
(*p<0.05, before vs after). 
Sneezes TAME 
Weeks 0 2 4 6 Weeks 0 2 4 6 
2 0.798 ** 1 2 0.623* 1 
4 0.901 ** 0.915 ** 1 4 0.586* 0.873*** 1 
6 0.912** 0.853 ** 0.890 ** 1 6 0.703** 0.677* 0.405 1 
8 0.760 ** 0.912** 0.806 ** 0.809 ** 8 0.517 0.611* 0.756** 0.293 
Table 2. Correlation of total number of sneezes and total TAME-esterase activity in the 
lavage fluid at each visit (weeks 0 to 8) for the placebo-treated group (n = 1 3). Results are 
shown as rs (*p = <0.05, ** = p<0.0l, *** = p<0.001). 
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Study V. Proteinase Content of Mast Cells in the Nasal Mucosa; Effects of Natural 
Allergen Exposure and Local Corticosteroid Treatment 
Occasional MCT and MCTC but no metachromatic cells were detected in the epithelium in 3 
of 9 controls. In the stroma in the controls, MCT constituted 2.4 % of the immunopositive 
cells. The density of epithelial MCT, MCTC and metachromatic cells as well as stromal MCT 
was higher in the allergic patients than in the controls pre season (Figure 8). In the allergies, 
MCT comprised 92.4% of the epithelial and 25.9% of th e stromal immunolabelled cells pre 
season. Allergen exposure did not result in statistically significant numerical changes in 
epithelial or stromal immunopositive or metachromatic cells. Epithelial MCT were reduced 
after glucocorticoid treatment. Serial sections displayed higher numbers of immunopositive 
cells than of metachromatic cells in the controls and in allergic patients. The metachromatic 
cells comprised from 33% (epithelium) to 90% (stroma) of the immunopositive cells in atopic 
mucosa before and during the season. About 87% (epithelium) to 73% (stroma) of the 
metachromatic cells in the allergic patients and 47% (stroma) in the controls were sensitive to 
aldehyde fixation. There was a correlation between the proportions of MCT and of aldehyde-
sensitive metachromatic cells. 
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Figure 8. Box graphs showing medians and interquartile range for the density of MCJC and 
MCT i n pre-seasonal nasal biopsies in 9 controls and 17 allergies. (* = p<0.05, ** = 
p<0.01, atopics vs controls.) 
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METHODOLOGICAL CONSIDERATIONS 
Subject selection 
The allergic individuals were recruited among medical and engineering students, and among 
patients at the ENT clinic. No attempt was made to take into account the severity of the 
disease as an inclusion criterion. All patients reacted to the allergen challenge with an 
increase in nasal symptoms as well as in the objective parameters. As can be expected in an 
unselected patient material, the individual reactions varied considerably. The healthy controls 
were recruited from medical students and the hospital staff. 
Assessment of symptoms 
The first parameter utilised for monitoring of the results after nasal challenge, the subjective 
assessment of symptoms, remains valid (Blackley 1873). The symptoms quantitated are nasal 
congestion, rhinorrhea and nasal irritation. Counting sneezes provides a relatively more 
objective symptom index. The subjects assessed their symptoms on a five-point scale. This 
method may be too rough when it comes to the correlation between the symptoms and the 
different biological parameters measured and a visual analogue scale may be a better method 
to use in this situation as it gives more graded results. 
Allergen challenge 
Quantitating the amount of allergen used for challenge represents an essential component of 
any experimental system. The delivery system used (I - IV) is a liquid extract in a metered 
dose nasal spray pump that avoids the tactile stimulus from an extract-soaked paper disc 
placed in the nose and excludes the variability of systems utilising the subject its own effort 
for delivery of the offending agent. Although quantification of the stimulus received by the 
subject is preferable, quantification of the stimulus delivered is an acceptable alternative. 
Anatomical differences between subjects can explain some of the apparent differences in 
subject reactivity. By utilising repeated challenges in the study design, this problem is 
minimised as each subject becomes his or her own control. As shown in Table 2, there was a 
high degree of correlation between the reactions in the different weeks in Study IV. It may be 
concluded from this that the lavage challenge procedure is a stable method giving validity to 
the results. 
Methods for sampling of biological material 
Biopsy is the method of choice to demonstrate the presence of a specific cell type in a tissue, 
but has its drawbacks as the number of time-points that can be obtained is limited. When 
studying the kinetics of putative cellular changes in the nasal mucosa, non-traumatic cell-
sampling techniques are preferable since repeated samples are required. The lavage technique 
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collects cells floating on the nasal mucosal surface and the brush technique harvests a 
proportion of cells within the epithelial lining (Pipkorn et al. 1988a, Greiff et al. 1990). Both 
techniques are non-traumatic, do not require anaesthetics, are easily tolerated and can be used 
for quantitative evaluation. As the interindividual variation in cell yield is greater than the 
intra-individual variation between different observations (Studies I and II), these methods can 
be used with preference for kinetic studies with repeated observations using each individual 
as his or her own control. Nasal lavage has been used for measuring changes in histamine and 
other mast-cell-associated mediators in nasal secretions before and after allergen challenge 
(Naclerio et al. 1983, Naclerio et al. 1985). This method results in a variable dilution factor 
that precludes the determination of m ediator concentrations in n asal secretions. The levels of 
mediators in nasal lavage obtained reflect the total amount of the mediator collected, which 
reflects the amount of mediator released. By the use of paper discs (Flowers et al. 1990) or by 
adding a tracer to the lavage fluid and calculating the dilution factor (Linder et al. 1983), the 
exact concentration of the mediator in the secretion can be determined. If resulting nasal 
secretions contain no significant levels of a mediator, as is the case for tryptase, unlike 
histamine, it will be easier to demonstrate an antigen-induced increase in lavage than in a 
paper disc as a wider mucosal area is surveyed. 
Drugs used in the study 
Fluticasone propionate and budesonide are both corticosteroids developed for topical use. 
They both have high activity in skin vasoconstriction tests and have been shown to be safe 
and give good clinical results (Phillipps 1990). To avoid total occlusion of the nasal cavity 
after allergen challenge, making lavage impossible, oxymetazoline was used in the lavage 
challenge model. The nasal decongestion does of course influence the degree of blockage the 
patients can experience (Naclerio et al. 1983). Despite this influence, the actively treated 
group reported less nasal congestion than the placebo group on the challenge after 4 weeks of 
treatment (IV). In the biopsy procedure, anaesthetics in combination with decongestants are 
used to eliminate pain and bleeding after the biopsy. Theoretically, this may affect the cells in 
the specimen as well as the volume of the tissue and thereby the results. Biopsy without these 
manoeuvres would probably not be approved by the ethics committee and make subject 
recruitment difficult. For all drugs used in this study, the doses are the recommended for 
clinical use. 
Staining and cell counting methods 
The methods used in this study identify distinctive properties of the mast cells: the granular 
content of glycosaminoglycan, chymase and tryptase, and IgE antibodies bound to high-
affinity IgE receptors. These properties, with the exception of the proteases, are shared with 
the closely related blood basophil. Tryptase appears to be more or less specific for the mast 
cell (Schwartz et al. 1987). Under normal or undisturbed conditions, close correlation 
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between cell numbers obtained using these methods is to be expected. Selective changes in 
any of these properties, resulting in cha nges or absence of such correlation, are the likely 
effects of functional activation of the cells, e.g. release of mediators or redistribution of IgE. 
The double-labelling technique for the identification of the MCR and MCtC is based on the 
principle that the chymase labelling and the resulting staining product effectively prevent the 
tryptase epitopes, present in all mast cells, from binding to the anti-tryptase antibody in the 
second labelling cycle (Irani et al. 1989) (V). In th e cytological samples the total number of 
positively stained cells was counted and no consideration given to the total number of cells on 
each slide (I, II). The prerequisite for this is that the samples have a relatively stable number 
of cells. By doing a differential count, this interobservation variability is eliminated. In the 
brush and lavage cytospin samples, the positively stained cells were too few to make a 
differential count practical. Furthermore, the metachromatic, IgE- and tryptase-staining 
methods used in Study II, all have different dyes for the background staining, thereby staining 
different proportions of the cells, making it impossible to compare results of differential 
counts obtained with different staining methods. In Study V, the p oint-counting method and 
the use of a square eyepiece graticule to d etermine the area surveyed for cells have the 
advantage that the area and the cells are simultaneously measured by the observer. 
Histamine, TAME and tryptase analysis 
Histamine has been shown to be unstable in b iological solutions. It is deactivated and the 
analyses use for detecting histamine also react to other amines (McBride et al. 1988). The 
RIA used in Studies III and IV is 50 times as sensitive as the HPLC used in Studies I, II and 
IV. The Immunotech-RIA® is specific to histamine and does not determine the first 
degradation product of histamine, methylhistamine, in contrast to the traditional OPT 
reaction-based methods and the Pharmacia-RIA® (Hammar et al. 1990). The significance of 
this remains to be evaluated. (III, IV) 
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DISCUSSION 
The upper and lower airways possess structural similarities and also appear to possess similar 
characteristics of allergic inflammation. Furthermore, the upper airways are far more 
accessible for investigations in vivo than the lower. Thus, the nasal mucosa is suitable for 
investigations of human airways in health and disease. Seasonal allergic rhinitis lends itself 
well to study for several reasons. Firstly, it affects a large percentage of the population, thus 
making it relatively easy to acquire a sufficient number of patients for study. Secondly, most 
patients are young and free of other underlying diseases that may confound the interpretation 
of results. Thirdly, the subjects can be studied during a period of the year when they are free 
from symptoms. Nasal challenge was chosen as the experimental method because it can 
answer questions about the pathophysiology of the disease and the action of drugs. In the 
laboratory full control can be achieved regarding the dose of challenge agent and timing of 
the challenge. One should be aware of the fact that challenge experiments are artificial 
situations which cannot mimic the continuous exposure occurring during natural exposure. 
Thus, certain important events may only be apparent during natural allergen exposure. It is 
therefore important to confirm results from the laboratory in the natural disease. Pollen is one 
of the major allergen sources in Scandinavia. At least one in every ten Scandinavians has a 
nasal allergy and it is estimated that pollen allergy accounts for half of these cases (Åberg 
1989, Varjonen et al. 1992). Thus patients with seasonal allergic rhinitis provide a relevant 
population for the study of allergic inflammation. 
Correlation between mast cells, mediators and symptoms 
The differences between the allergic patients' reactions to allergen versus diluent and the 
difference between the allergic patients and healthy controls regarding mast-cell density and 
the liberation of mast-cell markers are apparent. The allergies had increased numbers of mast 
cells in their mucosa even in the resting stage and the patients reacted to the allergen 
challenges with an increase in symptoms and biological markers but the healthy subjects did 
not. Control challenges with diluent prove that these changes were specific for the allergen. 
Challenging the nose with histamine generates a symptom pattern relevant to that seen after 
allergen challenge (Pipkorn 1988). An increase in the nasal lavage level of histamine was 
observed (III, IV) and the histamine/metachromatic cell quotient decreased after the allergen 
challenge, suggesting a secretion of the cellular histamine. The tissue histamine correlated 
with the tissue mast-cell density and the total number of mast cells per cytospin slide from 
brush samples correlated with the cellular histamine as well as the symptoms. It is therefore 
reasonable to conclude that the post-allergen challenge increase in symptoms is caused by 
mast-cell degranulation and secretion of mediators such as histamine. 
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The cellular kinetics after allergen provocation and during the pollen season 
There are many reports of an increase in the numbers of mast cells and basophils in nasal 
mucosa of allergic patients as a reaction to allergen exposure (Okuda et al. 1983, Otsuka et al. 
1985, Enerbäck et al. 1986a, Davies et al. 1987, Viegas et al. 1987, Bascom et al. 1988, 
Gomez et al. 1988, Liu 1988, Pipkorn et al. 1988b, Enerbäck et al. 1989, Pipkorn et al. 1989, 
Bachert et al. 1990, Borres et al. 1990, Lozewicz et al. 1990, Bentley et al. 1992, Iliopoulos et 
al. 1992). In this Study, several methods of identifying these cells have been employed in a 
parallel manner and all have shown an increase in the mast cell markers 8 to 12 hours after 
allergen challenge. This supports the hypothesis that a redistribution of mast cells towards the 
mucosal surface is part of the allergic inflammation in mucous membranes. On the other 
hand, the study on the effect of the pollen season did not show any statistically significant 
changes in mast cell density in either epithelium or stroma in non-steroid-treated patients. 
Results in line with this are found in the literature (Wihl and Mygind 1977, Pipkorn et al. 
1988d, Lozewicz et al. 1992, Varney et al. 1992). Differences in study design, patient 
selection, cell counting method or fixation and staining techniques (Trotter et al. 1990, 
Nakamura et al. 1991) as well as differences in timing of the studies, with different degrees of 
mast-cell secretion and mediator depletion, interfering with the demonstrability of the mast 
cells, all influence the results. In the pre-challenge samples in Study II a larger number of 
IgE-positive cells than metachromatic or tryptase-containing cells was found. The correlation 
between IgE-positive cells and the histamine content of the cell pellets was also poor. These 
findings can be interpreted as a sign of degranulation of mast cells in the epithelium. Such 
"ghost cells" could represent cells that have lost their granules but still bear IgE molecules 
linked to the Fce-receptors on their surface (Fokkens et al. 1992). The possibility that these 
IgE-positive cells could represent non-mast cells, with low-affinity Fce-receptors, appears 
less likely on the grounds of morphology and the fact that the immunohistochemical staining 
method does not detect cells with a low IgE content (Rognum and Brandtzaeg 1989, Bachert 
et al. 1990). The fact that the IgE-positive cells did not increase in number as much as the 
metachromatic cells during the late observation hours could indicate that the latter must reach 
a certain stage of maturation before they acquire IgE in amounts detectable by 
immunohistochemical staining methods. 
Release of mediators 
An increasing number of papers are reporting that the levels of tryptase in nasal lavage fluid 
are increased in patients with allergic rhinitis, both during native disease and after local 
allergen challenge (Castells and Schwartz 1988, Proud et al. 1992, Rasp et al. 1993). In 
Studies III and IV tryptase was compared with other markers of the allergic inflammatory 
response, TAME-esterase activity and histamine. The relationship between the total 
generation of tryptase and histamine indicates that these two markers are released together. 
Furthermore, there was a high degree of correlation between the individual levels of TAME-
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esterase and tryptase. This was not surprising since 25-30 % of the TAME-esterase activity 
measured in t he challenge situation represents tryptase activity, while the remainder largely 
represents plasma kallikrein activity (Baumgarten et al. 1986). In the resting stage, levels of 
tryptase are not above the limit of detection. This appears to contrast with the findings 
relating to histamine. High and variable baseline histamine levels in n asal lavage fluid are 
constantly reported (Naclerio et al. 1983, Pipkorn et al. 1987a, Pipkorn et al. 1987b, Bisgaard 
et al. 1988, Linder et al. 1988). In S tudy I the allergen challenge resulted in significantly 
lower histamine cell pellet contents and histamine/metachromatic cell quotient. This was 
taken as evidence of mast-cell activation and the loss of intracellular histamine. These 
findings lend further support to the concept that mast-cell activation is an essential ingredient 
in the immediate allergic response. 
The effects of topical corticosteroid treatment 
Reduction of the numbers of mast cells (Otsuka et al. 1986, Gomez et al. 1988) and mast-cell 
markers in nasal lavage fluid (Pipkorn et al. 1987a) have previously been recorded after 
topical g lucocorticosteroid treatment of allergic nasal mucosa. In o ther publications on the 
effect on mast cells after corticosteroid pretreatment, varying results have been reported 
(Pipkorn 1983, Lozewicz et al. 1992). The results of Study IV show that the actively treated 
patients reported fewer symptoms than the placebo group. There was also a reduction in the 
release of tryptase after 4 weeks' treatment with topical corticosteroid. The specificity of 
tryptase in mast-cell-mediated reactions is demonstrated in this study as it was the only 
marker able to manifest the effect of the corticosteroid treatment. In S tudy V t he epithelial 
numbers of MCt were reduced after steroid treatment. The reduction of MC'tC numbers did 
not reach statistical significance, however, probably due to the small number of subjects 
treated. In Study IV no change in mast-cell density after the treatment period was detected. 
Perhaps a more specific means of mast-cell detection, such as using immunolabelling with 
tryptase and chymase antibodies, or separate analysis of cellular findings in epithelium and 
stroma, would reveal other results. The changes in immunoregulation after glucocorticoid 
treatment are complex and may include all phases of the allergic response. Corticosteroid 
treatment does not seem to inhibit the release of his tamine and other mediators from human 
mast cells isolated from skin, intestine and airways after challenge with anti-IgE (Cohan et al. 
1989). The reduction in numbers of epithelial mast cells induced by the glucocorticosteroid 
treatment may thus be due to the inhibition of the production of mast-cell growth factors by 
mucosal T lymphocytes either by a direct action on the T-helper cells (Culpepper and Lee 
1985, Burke et al. 1992) or by acting on the antigen-presenting cells (Martinet et al. 1992). 
The heterogeneity among the patients 
The heterogeneity of the patient population is worth special consideration. Although in 
Studies I - V the patients showed a wide spectrum of reactions and the results varied between 
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patients, this heterogeneity was best demonstrated in Studies I and II. Three of the patients 
had elevated pre-challenge numbers of eosinophils and mast cells and high numbers of IgE-
bearing and tryptase-containing cells and reacted to the challenge with the most pronounced 
response. These findings suggest that a group of asymptomatic allergic individuals have an 
activated inflammatory system readily capable of vivid reactions to an offending antigen. 
Possible explanations for such a forceful inflammatory reaction may be sought in a different 
duration of the allergic disease, different degree of atopic heredity or a subclinical 
sensitisation to other allergens such as perennial allergens. 
The identity of the metachromatic cells 
It is of considerable biological interest to be able to decide the identity of the metachromatic 
cells in the nasal mucosa and the role of mast cells and basophils in mucosal allergy. Based 
on light-microscopic morphology and ultrastructural observations as well as on the finding of 
a naphthol-AS-D chloroacetate esterase activity, studies have indicated that the majority of 
metachromatic cells in the nasal epithelium are mast cells rather than blood basophils 
(Pipkorn et al. 1988c). Supported on histological and biochemical studies, basophils have 
been implicated in the late-phase reaction (Naclerio et al. 1985, Bascom et al. 1988, 
lliopoulos et al. 1992). In Study II, most of the metachromatic cells of the pre-challenge brush 
samples had a mast-cell-like morphology and their numbers correlated with the number of 
tryptase-positive cells. In samples taken 8 h to 12 h after the allergen challenge, 
metachromatic cells were far more numerous than tryptase-containing cells. In these samples 
an increase was noted in cells with lobulated nuclei, suggesting a basophil derivation. There 
was also an influx of rather small but strongly metachromatic cells which had no counterpart 
in the anti-IgE and anti-tryptase-stained specimens. The finding of an increase in cells 
resembling basophils in the late-phase samples is in agreement with reports that basophils 
may be a major source of metachromatic cells in the late-phase reaction (Naclerio et al. 
1987). An increase in the cells that had the morphology of mast cells and an increase in 
tryptase-containing cells was also noted. Cells containing tryptase in such quantity that it 
enables visualisation with immunochemical staining methods using anti-tryptase antibodies 
are probably not basophils (Castells et al. 1987). These findings taken together can only be 
interpreted as an indication of an influx of mast cells as well as of basophils into the allergic 
nasal mucosa during the late-phase reaction. In Study V the biopsy specimens contained more 
tryptase-containing cells than metachromatic cells. This can be an indication that the 
basophils are not a major source of metachromatic cells in these samples. The exact nature of 
the metachromatic cells can only be determined by using specific morphological markers for 
basophilic granulocytes as well as for mast cells. It has been reported that metachromatic cells 
recovered from nasal lavage fluid after allergen challenge carried CD 18, a typical leukocyte 
marker, indicating a basophil lineage (lliopoulos et al. 1992). 
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The mast cell heterogeneity - sign of functional differentiation 
In the rat, a strict compartmental segregation exi sts between the mucosal mast cell (MMC) 
and the connective tissue mast cell (CTMC). In Study V nasal mucosa in non-atopic controls 
was found to contain predominantly MCJC while high fractio ns of MCT were detected in 
allergic nasal mucosa, both in the stroma and, predominantly, in the epithelium. Furthermore, 
intra-epithelial MCTC were found in allergic patients as well as non-atopic individuals. 
These findings conflict with the hypothesis that mast cells of the M CT category may be the 
human equivalent of t he MMC found in rodents and MCTC the counterpart of the rodent 
CTMC (Miller and Schwartz 1989, Irani and Schwartz 1990). It would be more reasonable to 
interpret these findings as that the lack of chymase reflects functional activation of the mast 
cells rather than phenotypic differentiation. The correlation between numbers of protease -
containing mast cells and metachromatic cells was strong. Allergic nasal epithelium exhibited 
the largest difference in metachromatic cells and immunopositive mast cell density. The 
glycosaminoglycan content of some mast cells therefore appears to be too low to be 
demonstrable with toluidine blue staining whereas the mast cells may contain high enough 
quantities of protease to perm it immune labelling, indi cating that th e mast cell content of 
proteases and glycosaminoglycan can vary independently. Stimulated or newly recruited mast 
cells may thus display asynchrony in the acquisition or secretion of gl ycosaminoglycan and 
protease. A correlation between the fractions of ald ehyde-sensitive mast cells and the MCT 
was found. Absence of chymase thus appears to de crease the dye-binding ability of the 
glycosaminoglycan and increase the dye-binding blocking effect of aldehyde fixation. This is 
an indication of altered functional characteristics of the mast cells in allergic inflammation 
rather than a sign of phenotypic differentiation related to anatomical site. 
Mast cell function in the allergic inflammation 
The atopic patients displayed high numbers of epithelial mast cells and a recruitment of mast 
cells into the epithelium after allergen challenge (I, II, V). This phenomenon is of 
fundamental pathophysiological importance in the establishment of contact between a ero-
allergens and the mast cells in allergic conditions. Interestingly, both MCT and MCTC were 
seen in the epithelium of normal subjects and in the allergic patients (V). MCT was, however, 
clearly the dominating type of intra-epithelial mast cell in allergic patients. The 
metachromatic properties of these cells were also found to be reduced and highly aldehyde 
sensitive. These findings as well a s the detection of high levels of t he mast cell mediators 
histamine and tryptase in nasal lavage fluid from allergic patients after allergen challenge (III, 
IV), make it evident that the mast cells are actively involved in the allergic inflammation, are 
functionally altered and serve as secretory cells giving rise to the s ymptoms of an acute 
allergic reaction. The theories about how mast cells contribute to allergic disease are 
undergoing dramatic changes. This study focuses on the participation of mast cells in the 
acute allergic reaction. A concep t is put forward of the mast cell as a functionally altered, 
44 
primary effector cell with secretory activities responsible for the early allergic symptoms. The 
recognition of mast cells as a source of c hemotactic factors and multifunctional cytokines, 
acting on other inflammatory cells and the endothelial cells to regulate cell traffic, as well as 
the capacity of the mast cell for autoregulation of the IgE-mast cell-eosinophil response has 
led to the development of a concept of a cell that is capable of orchestrating an ongoing 
allergic inflammation. 
Future tasks 
Clinically asymptomatic subjects should be studied regarding fluctuation in morphological 
and biological markers. This might help to understand the so called "baseline", that all 
changes in the different parameters are compared with. The heterogeneity among the allergic 
patients needs to be analysed to find the distinguishing criteria for the group of patients that 
are high responders to allergen challenge. It is not known whether these patients are liable to 
become more allergic, multiallergic or develop allergy in other locations of the airways. This 
group might have special clinical requirements regarding medication or controls. There are no 
studies comparing the reaction to allergen exposure in multiallergic patients with the reaction 
in monoallergic patients. The exact nature of metachromatic cells in the nasal mucosa should 
be clarified using specific markers for mast cells as well as basophils. The kinetics of the 
tryptase release in relation to the histamine release after nasal allergen challenge is not clear. 
It should be analysed how these markers appear in and on the mucosal surface, both during 
the acute phase of the allergic reaction and over a longer time span, thereby increasing our 
knowledge of the function of the mast cells in the subsequent phases in the allergic 
inflammation. 
Although the disease studied here is seasonal allergic rhinitis, the methods applied can be 
utilised for the study of other clinical entities, e.g. perennial allergic rhinitis, occupational 
rhinitis due to exposure to chemical or physical irritants, vasomotoric rhinitis and infectious 
rhinitis. Mast cells have an active function in the acute allergic response and in chronic 
allergic inflammation. With an increased understanding of the different types of mast cells, 
the mediators they produce and how they are regulated, we will be in a better position to 
control the diseases in which these cells are implicated. 
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SUMMARY 
• Mast cells are increased in number in the nasal mucosal epithelium in patients with 
allergic rhinitis. 
» The intra-epithelial mast-cell density correlates with the degree of symptoms after 
allergen provocation as a sign that these cells are of pivotal importance for the 
symptoms. 
• The histamine content of the mast cells decreases and mast-cell markers in nasal 
lavage fluid increase after allergen provocation as a sign of degranulation of the cell as 
a reaction to the provocation. 
• The increase in m etachromatic cells with the morphology of mast cells and tryptase -
positive cells in the nasal epithelium 8-10 h and 12 h respectively after the 
provocation is a sign of recruitment of mast cells into the shock organ. 
• Metachromatic cells with morphology resembling the basophilic granulocyte appear 
in the epithelium in increased numbers 8 - 12 h after allergen challenge. 
• The higher number of immunopositive cells compared with metachromatic cells in 
biopsy specimens from allergic patients indicate that the mast cell content of proteases 
and glycosaminoglycans can vary independently. 
• The decrease in demonastrable glycosaminoglycans and the increased aldehyde 
sensitivity of mast cells from allergic patients as well as the fact that this increase 
consists mostly of cells containing tryptase, but lacking chymase, is a sign of altered 
functional characteristica of the mast cells in allergic inflammation. 
• The decrease in the post-allergen-challenge nasal lavage fluid tryptase levels and the 
decrease in the density of mast cells containing tryptase but lacking chymase in the 
nasal epithelium after topical corticosteroid treatment may explain the clinically 
beneficial effects of this treatment. 
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